TY - JOUR
T1 - Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia
AU - Karmali, Reem
AU - Larson, Melissa L.
AU - Shammo, Jamile M.
AU - Basu, Sanjib
AU - Christopherson, Kent
AU - Borgia, Jeffrey A.
AU - Venugopal, Parameswaran
N1 - Funding Information:
This project was funded in part by the Leukemia Pilot Project Grant from the Rush University Cancer Center. Funds were also graciously provided by the Samuel G. Taylor III chair.
Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2015/11/2
Y1 - 2015/11/2
N2 - Our objective was to explore associations of circulating factors implicated in insulin-like growth factor-1 receptor (IGF-1R) signaling with clinical outcomes of patients with acute myeloid leukemia (AML). Pretreatment blood samples from patients with non-M3 AML (n = 30) were collected prospectively and levels of IGF binding proteins (IGFBPs) 1-7 and IGF-1 (free and total) were established at diagnosis and statistically evaluated. Baseline levels of IGFBP-1 and-6 below respective thresholds of 8.8 ng/mL and 237 ng/mL were associated (p = 0.0347 and 0.0099, respectively) with superior progression-free survival, whereas baseline levels of IGFBP-1,-2,-6 and-7 below the respective thresholds of 8.8, 28.8, 237 and 119 ng/mL were strongly associated (p = 0.0004, 0.0085, 0.0031, 2.46 × 10-7, respectively) with improved overall survival. These findings provide promising evidence that IGFBP signatures could be used as predictive tools in AML, with applications in remission surveillance and the development of IGFBP-directed biologic therapy.
AB - Our objective was to explore associations of circulating factors implicated in insulin-like growth factor-1 receptor (IGF-1R) signaling with clinical outcomes of patients with acute myeloid leukemia (AML). Pretreatment blood samples from patients with non-M3 AML (n = 30) were collected prospectively and levels of IGF binding proteins (IGFBPs) 1-7 and IGF-1 (free and total) were established at diagnosis and statistically evaluated. Baseline levels of IGFBP-1 and-6 below respective thresholds of 8.8 ng/mL and 237 ng/mL were associated (p = 0.0347 and 0.0099, respectively) with superior progression-free survival, whereas baseline levels of IGFBP-1,-2,-6 and-7 below the respective thresholds of 8.8, 28.8, 237 and 119 ng/mL were strongly associated (p = 0.0004, 0.0085, 0.0031, 2.46 × 10-7, respectively) with improved overall survival. These findings provide promising evidence that IGFBP signatures could be used as predictive tools in AML, with applications in remission surveillance and the development of IGFBP-directed biologic therapy.
KW - AML
KW - IGF-1
KW - IGFBPs
KW - Luminex
KW - clinical outcome
UR - http://www.scopus.com/inward/record.url?scp=84947705312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947705312&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1022767
DO - 10.3109/10428194.2015.1022767
M3 - Article
C2 - 25735964
AN - SCOPUS:84947705312
SN - 1042-8194
VL - 56
SP - 3135
EP - 3142
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -
